Episode 28: APOL1 Screening and Early Detection - Patient and Clinician Perspectives
In the final episode of KDIGO’s three-part Conversations in Nephrology series on APOL1 kidney disease, host Kirk Campbell, MD (University of Pennsylvania, United States), speaks with Titilayo Ilori, MD (Boston University, United States), and kidney health advocate Joshua Albright (United States) about how APOL1 genetic testing can shape the future of kidney care. Their conversation brings together clinical expertise and lived experience to examine why early detection matters, how to overcome barriers to equitable testing, and what it will take to turn awareness into meaningful action for patients and communities.Learn more and access resources from the KDIGO Controversies Conference on APOL1 Kidney Disease: https://kdigo.org/conferences/apol1-kidney-disease/This podcast was supported by Vertex Pharmaceuticals.
--------
13:30
--------
13:30
Episode 27: Management of Patients with APOL1 Kidney Disease
In this second installment of KDIGO’s three-part podcast series on APOL1 kidney disease, host Kirk Campbell, MD (University of Pennsylvania, United States), welcomes Barry Freedman, MD (Wake Forest University School of Medicine, United States) for a practical discussion on patient management. They examine how APOL1 risk variants influence progression, review current therapeutic approaches, and explore emerging targeted treatments designed to improve care and outcomes for affected individuals.Learn more and access resources from the KDIGO Controversies Conference on APOL1 Kidney Disease: https://kdigo.org/conferences/apol1-kidney-disease/This podcast was supported by Vertex Pharmaceuticals.
--------
19:15
--------
19:15
Episode 26: Burden and Pathophysiology of APOL1 Kidney Disease
This is the first episode of a three-part KDIGO Conversations in Nephrology series on APOL1 kidney disease. Host Kirk Campbell, MD (University of Pennsylvania, United States), speaks with Bessie Young, MD (University of Washington, United States) about the discovery, burden, and biology of APOL1 kidney disease. Their discussion explores how APOL1 variants contribute to increased kidney disease risk in people of African ancestry, recent findings on protective variants, and ongoing research toward targeted therapies.Learn more and access resources from the KDIGO Controversies Conference on APOL1 Kidney Disease: https://kdigo.org/conferences/apol1-kidney-disease/This podcast was supported by Vertex Pharmaceuticals.
--------
13:00
--------
13:00
Episode 25: Treatment Revolution in Iga Nephropathy
Join Dana Rizk, MD (University of Alabama at Birmingham, USA), and Shikha Wadhwani, MD (Indiana University School of Medicine, USA), for a conversation on the treatment revolution in IgAN. They discuss how breakthroughs in understanding disease pathophysiology are fueling a wave of new therapies that go beyond traditional supportive care. Key topics include what's changed since the KDIGO 2021 Guideline, the four-hit hypothesis and its role in driving novel therapies, key factors to consider when selecting treatments, and the evolving role of traditional approaches alongside newer agents.This podcast was supported by Travere.
--------
14:30
--------
14:30
Episode 24: Overview of the Latest Guidance in IgA Nephropathy Management
Join Dana Rizk, MD (University of Alabama at Birmingham, United States), and Brad Rovin, MD (Ohio State University, United States), Co-Chair of the 2025 KDIGO IgAN/IgAV Guideline, for a deep dive into the latest updates in patient care. Their conversation explores the most important takeaways from the new guideline, the critical role of kidney biopsies in diagnosis and prognosis, the use of the IgAN prediction tool for risk assessment, and the updated thresholds and treatment goals designed to improve outcomes.This podcast was supported by Travere.
Brasil